Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Atopic dermatitis inducer

a technology of inducer and atopic dermatitis, applied in the field of inducer, can solve the problems of not being able to provide essential treatment and not paying attention to the substances produced in the body, and achieve the effect of reducing symptoms

Inactive Publication Date: 2006-06-22
SHIONOGI & CO LTD
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention provides an atopic dermatitis inducer that is a purified human secretion fraction or an antigenic molecule or antigen determinant in the purified fraction that is obtained through a process of filtering, collecting, and separating. The invention also provides an antibody that binds to the inducer and a method of diagnosing atopic dermatitis using the inducer or antibody. The invention also provides a drug for desensitization therapy of atopic dermatitis that contains the inducer as an active ingredient. The inducer can be a specific component of a human secretion or a foreign substance present in the body. The invention addresses the problem of atopic dermatitis by providing a method for diagnosing and treating the disease.

Problems solved by technology

A method of administering an inhibitor of production of an IgE antibody against an antigen shows an effect to a certain device, however, it does not essentially block the pathogen, and therefore, although it is useful in alleviating symptoms, it is not an essential treatment.
In addition, since the origins of pathogens have been sought only from food or foreign substances present in the environment, no attention was paid to substances produced in the body.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Atopic dermatitis inducer
  • Atopic dermatitis inducer
  • Atopic dermatitis inducer

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0077] Purification of Fraction Having Histamine-Releasing Activity (Fr.D)

1-1. Step of Filtering Human Sweat, Removing Insoluble Matters and Collecting the Filtrate

[0078] 500 ml of human sweat was filtered (0.22 μm), and the precipitate was removed. A filtrate with a total protein amount of 1.07 mg roughly estimated from the optical density (OD, 280 nm) was obtained,

1-2. Step of Mixing the Filtrate with a ConA-Affinity Carrier and Collecting the Supernatant

[0079] To the sweat subjected to filtering, 24 ml of a ConA-affinity carrier (ConA-Sepharose, Amersham Pharmacia; glycoprotein adsorption capacity: 45 mg / ml) was added, and stirring was carried out overnight at 4° C., and then the supernatant (a fraction not adsorbed to ConA-Sepharose) was collected.

1-3. Step of Separating the Supernatant with an Anionic Exchange Column and Collecting a Fraction Having a Histamine-Releasing Activity

[0080] Onto an anionic exchange column (MonoQ HR 10 / 10; Pharmacia Biotech), which had been ...

example 2

Effect of Serum of Patient with Atopic Dermatitis on Histamine-Releasing Activity of Fr.D

[0083] Fr.D was collected, lyophilized, redissolved in PBS at a concentration of 1 mg / ml and used as an Fr.D standard. When 10 μl of a 50-fold dilution of the Fr.D standard was added to 40 μl of the serum of a patient with atopic dermatitis and preincubation was carried out at 37° C. for 30 minutes, the histamine-releasing activity was completely lost. On the contrary, when the serum of a normal subject was added, the histamine-releasing activity was not lost (FIG. 5). “antiIgE” and “Fr.D (×500)” are a positive control, and “serum (AD)” (serum of a patient) and “serum (N)” (serum of a normal subject) are a negative control.

example 3

Enzyme Treatment

3-1. DNase Treatment and Lipase Treatment

[0084] To 5 μl of the Fr.D standard, DNase (Ambion) was added at a final concentration of 0.2 U / μl, or a pancreatic lipase (SIGMA) was added at a final concentration of 30 mU / μl, and incubation was carried out at 37° C. for 16 hours. In both cases, a decrease in the histamine-releasing activity was not observed.

3-2. Protease Treatment

[0085] To 5 μl of the Fr.D standard, 2 μg / μl of ProteinaseK (Ambion) or 2 μg / μl of Trypsin (SIGMA) was added to give a final concentration of 0.1 μg / μl, and incubation was carried out at 37° C. for 16 hours. In both cases, the histamine-releasing activity was completely lost.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
pore sizeaaaaaaaaaa
Login to View More

Abstract

An atopic dermatitis inducer binding to a human own IgE antibody and activating mast cells and basophiles, which includes a purified human secretion fraction, or an antigenic molecule or an antigenic determinant in the purified fraction, and obtained through the following steps of: filtering a human secretion, removing insoluble matters and collecting the filtrate; mixing the filtrate with a ConA-affinity carrier and collecting the supernatant; and separating a component having a histamine-releasing activity from the supernatant by column chromatography. This inducer is effective in diagnosing and treating human atopic dermatitis.

Description

TECHNICAL FIELD [0001] The invention of this application relates to an atopic dermatitis inducer (hereinafter sometimes referred to as ‘inducer’) secreted by a patient with atopic dermatitis of his or her own, a method of diagnosing atopic dermatitis using this inducer or an antibody against the inducer, and a drug for desensitization therapy of atopic dermatitis containing this inducer as an active ingredient. BACKGROUND ART [0002] In recent years, the number of patients with atopic dermatitis is rapidly increasing and the ratio of the patients with atopic dermatitis to the patients who see a dermatologist exceeds 30%, and it becomes one of the major dermatitis. Atopic dermatitis is one of the atopic diseases caused by a hereditary factor that readily produces an IgE antibody against a common allergen, in addition to various environmental factors. The disease starts in infancy and runs a course of disease chronically with age, and becomes milder before puberty in many cases. Howeve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/567C12N5/08C07K16/42A61K39/35A61P17/00A61P37/08C07K14/47C07K16/18C12Q1/02G01N33/53
CPCA61K2039/505C07K14/47C07K16/4291A61P17/00A61P37/08C07K16/42C07K16/18
Inventor HIDE, MICHIHIROTANAKA, TOSHIHIKOTANAKA, AKIOISHII, KAORISUZUKI, HIDENORI
Owner SHIONOGI & CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com